Produktname:5-bromo-6-chloro-2,2-difluorobenzo[d][1,3]dioxole

IUPAC Name:5-bromo-6-chloro-2,2-difluoro-2H-1,3-benzodioxole

CAS:869188-52-3
Molekulare Formel:C7H2BrClF2O2
Reinheit:95%
Katalognummer:CM126179
Molekulargewicht:271.44

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM126179-250mg in stock ŢźǕ
CM126179-1g 1-2 Weeks źƞƄ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:869188-52-3
Molekulare Formel:C7H2BrClF2O2
Schmelzpunkt:-
SMILES-Code:FC1(F)OC2=CC(Cl)=C(Br)C=C2O1
Dichte:
Katalognummer:CM126179
Molekulargewicht:271.44
Siedepunkt:
Mdl-Nr.:MFCD09759045
Lagerung:Store at 2-8°C.

Category Infos

Fluorinated Compounds
Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.

Column Infos

Fluorinated compounds
Fluorinated compounds refers to organic or inorganic compounds containing fluorine.
Zegocractin
CalciMedica announces positive topline data from phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP). The trial met primary objective with statistically significant dose response. Calcium release–activated calcium (CRAC) channels are involved in activating T cells, and responsible for regulating calcium-dependent inflammatory pathways or tissue cell injury pathways. AP is a potentially life-threatening inflammatory disease of the pancreas featured by aberrant signaling of calcium.
CalciMedica’s Auxora is a potent and selective intravenous formulated CRAC channel inhibitor containing the active ingredient Zegocractin. It is being developed for the treatment of acute inflammatory and immunologic illnesses, including severe AP, AIPT, AKI, and severe acute respiratory diseases including AHRF, and ARDS. 

Related Products